PDA

View Full Version : BGMD - BG Medicine Inc



asyefwxb08
09-22-2015,
BG Medicine, Inc. (BG Medicine) is a life sciences company focused on the discovery, development and commercialization of cardiovascular diagnostics to addresses unmet medical needs. The Company focuses on blood-based tests. Its lead product candidate in development is CardioSCORE, which is a multi-analyte biomarker-based blood test for atherothrombotic cardiovascular disease, commonly known as vulnerable plaque. In March 2011, the Company entered into a supply agreement with Health Diagnostic Laboratory, Inc. (HDL), pursuant to which HDL agreed to purchase manual galectin-3 test kits from the Company and to offer galectin-3 testing services to physicians in the United States. This manual version of Its Galectin-3 test is being marketed in the United States through a number of regional and national laboratory testing facilities. In addition, it has partnered with four diagnostic instrument manufacturers, which are developing automated instrument versions of its galectin-3 test.

AnyaRednPar
09-22-2015,
BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock
1 days 3 hours 34 minutes ago - GlobeNewswire via Comtex


BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced the sale of 6,000,000 shares of its common stock in an underwritten public offering at a price to the public of $2.00 per share. The net offering proceeds to BG Medicine from the sale of the shares are expected to be approximately $11.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses, but excluding any exercise of the underwriter's over-allotment option.

BG Medicine anticipates using the net proceeds from this offering for its operations, including, advancing the commercialization of its cardiovascular diagnostic tests in the United States and Europe; and other general corporate purposes, including capital expenditures, licensing of intellectual property, repayment of indebtedness and working capital.

The offering is expected to close on or about January 30, 2013, subject to customary closing conditions. In addition, BG Medicine has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock on the same terms and conditions, solely to cover over-allotments, if any.

Lazard Capital Markets LLC is acting as the sole book-running manager for the offering.

The shares described above will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission ("SEC"). The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to: Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, NY 10020 or via telephone at (800) 542-0970. BG Medicine intends to file a final prospectus supplement relating to the offering with the SEC, which will be available along with the accompanying prospectus filed with the SEC in connection with the shelf registration, on the SEC's website at www.sec.gov.

Aqndionlj
09-23-2015,
not the usual time for a secondary offer...near all time lows here...but of course they did gice it a false bump/pump so at least it was over 1.00 when they needed the cash ... of course they can r/s now ...then that would make some under handed sense lol

boroVika
09-24-2015,
resistance breaking to the 1.30's possible